PFKP and diabetes mellitus: The molecular understanding of PFK isoform selectivity, coupled with future studies of the pyrazolo-oxazepine scaffold, could open the door to selective activation of PFKM and PFKP, and the development of new pharmacological therapies for diabetes and cancer.